Pharma: Other News To Note
Monday, July 29, 2013
Astrazeneca plc, of London, and Bristol-Myers Squibb Co., of New York, said the FDA acknowledged receipt of the new drug application resubmission for investigational drug dapagliflozin for the treatment of adults with Type II diabetes.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.